Literature DB >> 10515397

Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies.

S Majumdar1, D Li, T Ansari, P Pantelidis, C M Black, M Gizycki, R M du Bois, P K Jeffery.   

Abstract

Differences in the inflammatory response and prognosis of cryptogenic fibrosing alveolitis (CFA) and that associated with systemic sclerosis (FASSc) are beginning to emerge. It is hypothesized that these differences may be reflected in a distinct pattern of T-helper (Th)-1 and Th-2-type cytokines. Open lung biopsies were obtained from clinically well-documented cases of CFA and FASSc and, as a control, compared with grossly and histologically normal parenchyma obtained from smokers whose lungs were resected for cancer (n=5 in each group). In situ hybridization (ISH) was applied to the samples using anti-sense and sense 35S-labelled riboprobes to detect messenger ribonucleic acid (mRNA) for interleukins (IL)-2, IL-4, IL-5 and interferon (IFN)-gamma. Between 52-91% of cells expressing the cytokines studied were present in the alveolar interstitium rather than in lumenal cells or the alveolar epithelial lining. The highest values for all four cytokines were present in the patients with FASSc, i.e., 22-39 ISH positive cells x mm(-2) alveolar tissue compared with 1-19 cells x mm(-2) and 4-5 cell x mm(-2) in CFA and control subjects, respectively. Whereas the proportions of the four cytokines in FASSc were similar to the control subjects, IL-4 and IL-5 predominated significantly in CFA (p<0.001). For example, the ratio of IL-5 to IFN-gamma was 22:1 in CFA, significantly higher than in the cases with FASSc (2:1) or the control subjects (4:1) (p<0.05). In conclusion, cryptogenic fibrosing alveolitis is an inflammatory condition which is characterized, like asthma, by a predominance of gene expression for T-helper-2-type regulatory cytokines, whereas cryptogenic fibrosing alveolitis associated with systemic sclerosis appears to have a distinct mixed T-helper-1/T-helper-2 functional phenotype and a greater number of cells expressing each of these pro-inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515397     DOI: 10.1034/j.1399-3003.1999.14b03.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

Review 4.  Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling.

Authors:  Chun Geun Lee; Hye-Ryun Kang; Robert J Homer; Geoffrey Chupp; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2006-07

5.  Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in Mammalian lung fibrosis.

Authors:  Yang Zhou; Hong Peng; Huanxing Sun; Xueyan Peng; Chuyan Tang; Ye Gan; Xiaosong Chen; Aditi Mathur; Buqu Hu; Martin D Slade; Ruth R Montgomery; Albert C Shaw; Robert J Homer; Eric S White; Chang-Min Lee; Meagan W Moore; Mridu Gulati; Chun Geun Lee; Jack A Elias; Erica L Herzog
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

6.  Plexin C1 deficiency permits synaptotagmin 7-mediated macrophage migration and enhances mammalian lung fibrosis.

Authors:  Xueyan Peng; Meagan Moore; Aditi Mathur; Yang Zhou; Huanxing Sun; Ye Gan; Jose D Herazo-Maya; Naftali Kaminski; Xinyuan Hu; Hongyi Pan; Changwan Ryu; Awo Osafo-Addo; Robert J Homer; Carol Feghali-Bostwick; Wassim H Fares; Mridu Gulati; Buqu Hu; Chun-Geun Lee; Jack A Elias; Erica L Herzog
Journal:  FASEB J       Date:  2016-09-08       Impact factor: 5.191

7.  Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia.

Authors:  C Jakubzick; E S Choi; S L Kunkel; H Evanoff; F J Martinez; R K Puri; K R Flaherty; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

Review 8.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment.

Authors:  Nasreen Khalil; Robert O'Connor
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

10.  Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function.

Authors:  Sung-Woo Park; Mi-Hyun Ahn; Hee Kyung Jang; An Soo Jang; Do-Jin Kim; Eun-Suk Koh; Jong-Sook Park; Soo-Taek Uh; Yong Hoon Kim; Jai Soung Park; Sang Hyun Paik; Hwa-Kyun Shin; Wook Youm; Choon-Sik Park
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.